ADT impacts mood of patients with prostate cancer, as perceived by partners
the ONA take:
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer and those negative effects are concurrently observed by their partners, according to a new study published online ahead of print in the journal Psycho-Oncology.
For the study, researchers from Mount Allison University in Sackville, Canada, and the University of British Columbia in Vancouver, Canada, sought to assess the relationship between androgen deprivation therapy and the mood of patients with prostate cancer and their partners.
Researchers enrolled 295 patients and 84 partners. Participants completed an online survey evaluating the patients' current mood and mood prior to therapy, relationship adjustment, and sexual function. Results were compared with that of men who received non-hormonal treatments. Results showed that 82 patients currently treated with androgen deprivation therapy reported worsened mood compared with the 213 not on hormonal therapy. Researchers found that the 42 partners of patients on hormonal therapy reported declines in the patient's mood, but to a greater extent that the patient.
"The psychological changes related to ADT can impact relationships and affect the quality of life of both PCa patients and partners," the authors conclude. "Patients and their partners are likely to benefit from being well informed about the psychological effects of androgen deprivation on men beginning ADT."
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
- Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|